Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
We are pleased to introduce our new reports.
Decison Support Documents 2017
DSD 104: Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)
DSD 105: Prostate artery embolisation for benign prostatic hyperplasia
DSD 106: Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS
DSD 107: Repetitive transcranial magnetic stimulation for treatment-resistant major depression
DSD 108: Radiofrequency ablation for metastatic spinal lesions
DSD 21/Update 2017: Percutaneous disc volume reduction – chemonucleolysis
DSD 97/Update 2017: Leadless pacemakers for right ventricle pacing
As part of the professionalization of patients organizations and the expansion of their activities (eg. awareness campaigns, advisory services for patients and their relatives, etc.) the need for financial resources is also increasing. This need is often covered by pharmaceutical and medical device manufacturers. This update analyzed the extent of financial support for patient organizations from pharmaceutical companies in Austria in 2015. 36 of 116 PHARMIG member companies have declared donations to patient organization for the year 2015. A total sum of € 1.724.683 in grants to patient initiatives were reported by the PHARMIG member companies. Most grants (68%) were given to initiatives in the field of Oncology & Hematology, Neurology, Lung, Hepatitis, and Rheumatology.
Altogether there was a significant increase in disclosure in comparison to 2014. Both the number of pharmaceutical companies that declared financial contributions and the total sum of contributions has risen by 50%.
Publication: Rapid Assessment No. 7b/1. Update 2017: http://eprints.hta.lbg.ac.at/1125/
Contact: Philipp Petersen
We are pleased to introduce our two new HSO reports.
This Information is available in German only.
Claudia Wild of the Ludwig Boltzmann Institute Health Technology Assessment in Expert Panel of the European Commission
Director of the LBI-HTA, Claudia Wild, was elected to the "Expert Panel on Effective Ways of Investing in Health" of the European Commission. The members of the panel, selected in a rigorous selection process, advise the European Commission and the EU Member States on health care issues. In concrete terms, the expert group is currently working on the following topics: innovative payment models for cost-intensive new drugs, quality assessment of primary care and performance assessment of health systems. We are pleased that the importance of HTA is also being recognized at European level.
Research interests of Non-interventional studies (NIS) in Austria. Update of the systematic analysis.
The study questions of non-interventional studies (NIS) in Austria were evaluated again two years after the first report. NIS evaluate pharmaceuticals and medical devices after their marketing authorization for the approved indication in routine clinical settings. By law NIS do not have to be approved in Austria but need to be registered. A public database of NIS has to be made available to the interested public. On Aug. 7th, 2015, the initial reference date, LBI-HTA had evaluated the then 33 available summaries of final reports from the database from a total of then 251 registered NIS. On April 3rd, 2017 – the reference date of this update – already 72 summaries (plus 39) were available for evaluation from a total of now 325 (plus 74) registered NIS. So this update shows that over time more and more summaries of final reports are included in the public database. Most summaries are still formally incomplete. The most common research questions NIS addressed were effectiveness in practice and drug safety. The summaries of final reports answer their respective research questions with mostly exclusively positive results, only 2 of 72 NIS for which summaries are in the database also report negative results. 21 of 72 NIS are also registered in international trial registries and for 13 of 72 NIS scientific publications could be identified via Pubmed. The poor quality of the database (maintenance and control of content) has not improved in the almost two years since our initial report.
Publication: Rapid Assessment No. 7c Update: http://eprints.hta.lbg.ac.at/1122/
Contact: Claudia Wild
As part of the Horizon Scanning in Oncology (HSO) project, a generic tool was developed in English to give support for a budget-impact-analysis of oncology drugs. This tool can therefore be used as assistance for a budget-impact-calculation in the HSO project but also in other fields of oncology. It represents a raw version, which can be expanded or modified for any particular drug to be evaluated, e.g. with regard to diagnostic tests, the most frequent side effects, etc.. The practicality of the tool is illustrated by means of an application example of the oncology drug palbociblib. Because of the varying patient populations, the percentage of the target population on the hospital level must be added in order to be able to calculate the total costs for the medicinal product.